W-L FreshBurst Listerine Expanded Anticaries Clinical Test Urged By FDA
This article was originally published in The Rose Sheet
Executive Summary
Potential changes to the anticaries and antiplaque/antigingivitis monographs to allow a crossover product must be accompanied by stronger clinical studies than proposed by Warner-Lambert for FreshBurst Listerine with Fluoride, FDA advised the company at a June 6 OTC drug "feedback" meeting in Rockville, Md.
You may also be interested in...
W-L Listerine Anticaries Rinse Gingivitis Assessment Required - FDA
Acceptance of plaque reduction as the sole outcome of an experimental gingivitis model designed to demonstrate the antiplaque/antigingivitis activities of Listerine mouthrinse would be "premature," FDA told Warner-Lambert in a recent letter.
W-L Listerine Anticaries Rinse Gingivitis Assessment Required - FDA
Acceptance of plaque reduction as the sole outcome of an experimental gingivitis model designed to demonstrate the antiplaque/antigingivitis activities of Listerine mouthrinse would be "premature," FDA told Warner-Lambert in a recent letter.
W-L Listerine Anticaries Fluoride Rinse Altered Formula Proposed To FDA
Warner-Lambert has changed its proposed fluoride-containing oral anticaries/antiplaque/antigingivitis rinse to a .02% sodium fluoride formula to reflect results from recently conducted market research, W-L says in comments submitted to FDA May 15.